Radium Ra-223
- Generic Name
- Radium Ra-223
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- Ra
- CAS Number
- 15623-45-7
- Unique Ingredient Identifier
- 8BR2SOL3L1
- Background
Radium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).
- Associated Conditions
- -
- Associated Therapies
- -
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
- Conditions
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT03093428
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 52
- Registration Number
- NCT03002220
- Locations
- 🇪🇸
MedSIR Investigative site, Madrid, Spain
🇪🇸MedSIR investigative site, Palma De Mallorca, Spain
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2021-07-08
- Target Recruit Count
- 36
- Registration Number
- NCT02463799
- Locations
- 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸Tulane Cancer Center, New Orleans, Louisiana, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
- Conditions
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT02406521
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT02278055
- Locations
- 🇺🇸
New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.